MGMT mediates a DNA repair mechanism, and epigenetic silencing through methylation of the MGMT promotor confers a positive prognosis and predicts response to temozolomide (an alkylating agent) in patients with glioblastoma [8,11,18,24,25]. The gene discussed is MGMT; the disease is glioblastoma.